Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Angioleiomyoma of the inferior turbinate: a rare cause of isolated facial pain.

Heyman J, Jones LM, Hilton JM, Cooke JS, Viswanathan H, Hayes SM.

Ann R Coll Surg Engl. 2019 Jun 20:e1-e3. doi: 10.1308/rcsann.2019.0086. [Epub ahead of print]

PMID:
31219307
2.

Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI).

Matza LS, Brazier JE, Stewart KD, Pinto L, Bender RH, Kircik L, Jordan J, Kim KJ, Mutebi A, Viswanathan HN, Menter A.

J Med Econ. 2019 Sep;22(9):936-944. doi: 10.1080/13696998.2019.1627362.

PMID:
31161828
3.

Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients.

Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Kawahara SH, Cowan RP, Dabbous F, Campbell KL, Shewale AR, Pulicharam R, Kowalski JW, Viswanathan HN, Lipton RB.

Cephalalgia. 2019 Apr;39(4):465-476. doi: 10.1177/0333102418825373. Epub 2019 Mar 9.

4.

Branching of hydraulic cracks enabling permeability of gas or oil shale with closed natural fractures.

Rahimi-Aghdam S, Chau VT, Lee H, Nguyen H, Li W, Karra S, Rougier E, Viswanathan H, Srinivasan G, Bažant ZP.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1532-1537. doi: 10.1073/pnas.1818529116. Epub 2019 Jan 11.

5.

Nasal obstruction secondary to an inverted midline supernumerary tooth.

Jones L, Hilton JM, Heyman J, Viswanathan H, Wreesmann VB, Hayes SM.

Ann R Coll Surg Engl. 2019 Jan;101(1):e14-e16. doi: 10.1308/rcsann.2018.0163. Epub 2018 Oct 5.

PMID:
30286632
6.

Quantifying Topological Uncertainty in Fractured Systems using Graph Theory and Machine Learning.

Srinivasan G, Hyman JD, Osthus DA, Moore BA, O'Malley D, Karra S, Rougier E, Hagberg AA, Hunter A, Viswanathan HS.

Sci Rep. 2018 Aug 3;8(1):11665. doi: 10.1038/s41598-018-30117-1.

7.

Modeling flow and transport in fracture networks using graphs.

Karra S, O'Malley D, Hyman JD, Viswanathan HS, Srinivasan G.

Phys Rev E. 2018 Mar;97(3-1):033304. doi: 10.1103/PhysRevE.97.033304.

PMID:
29776097
8.

Predictions of first passage times in sparse discrete fracture networks using graph-based reductions.

Hyman JD, Hagberg A, Srinivasan G, Mohd-Yusof J, Viswanathan H.

Phys Rev E. 2017 Jul;96(1-1):013304. doi: 10.1103/PhysRevE.96.013304. Epub 2017 Jul 10.

PMID:
29347061
9.

Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.

Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B.

Value Health. 2017 Sep;20(8):1174-1179. doi: 10.1016/j.jval.2016.11.020. Epub 2017 Jun 16.

10.

Arsenic mobilization in shallow aquifers due to CO2 and brine intrusion from storage reservoirs.

Xiao T, Dai Z, Viswanathan H, Hakala A, Cather M, Jia W, Zhang Y, McPherson B.

Sci Rep. 2017 Jun 5;7(1):2763. doi: 10.1038/s41598-017-02849-z.

11.

Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary.

Higgins PDR, Harding G, Revicki DA, Globe G, Patrick DL, Fitzgerald K, Viswanathan H, Donelson SM, Ortmeier BG, Chen WH, Leidy NK, DeBusk K.

J Patient Rep Outcomes. 2017;2(1):26. doi: 10.1186/s41687-018-0049-2. Epub 2018 May 30.

12.

Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diary.

Higgins PDR, Harding G, Leidy NK, DeBusk K, Patrick DL, Viswanathan HN, Fitzgerald K, Donelson SM, Cyrille M, Ortmeier BG, Wilson H, Revicki DA, Globe G.

J Patient Rep Outcomes. 2017;2(1):24. doi: 10.1186/s41687-018-0044-7. Epub 2018 May 9.

13.

Understanding hydraulic fracturing: a multi-scale problem.

Hyman JD, Jiménez-Martínez J, Viswanathan HS, Carey JW, Porter ML, Rougier E, Karra S, Kang Q, Frash L, Chen L, Lei Z, O'Malley D, Makedonska N.

Philos Trans A Math Phys Eng Sci. 2016 Oct 13;374(2078). pii: 20150426. doi: 10.1098/rsta.2015.0426. Review.

14.

Introduction: energy and the subsurface.

Christov IC, Viswanathan HS.

Philos Trans A Math Phys Eng Sci. 2016 Oct 13;374(2078). pii: 20150430. doi: 10.1098/rsta.2015.0430.

15.

CO2 Accounting and Risk Analysis for CO2 Sequestration at Enhanced Oil Recovery Sites.

Dai Z, Viswanathan H, Middleton R, Pan F, Ampomah W, Yang C, Jia W, Xiao T, Lee SY, McPherson B, Balch R, Grigg R, White M.

Environ Sci Technol. 2016 Jul 19;50(14):7546-54. doi: 10.1021/acs.est.6b01744. Epub 2016 Jun 30.

PMID:
27362472
16.

Analysis and Visualization of Discrete Fracture Networks Using a Flow Topology Graph.

Aldrich G, Hyman JD, Karra S, Gable CW, Makedonska N, Viswanathan H, Woodring J, Hamann B.

IEEE Trans Vis Comput Graph. 2017 Aug;23(8):1896-1909. doi: 10.1109/TVCG.2016.2582174. Epub 2016 Jun 20.

PMID:
27333605
17.

Clinical meaningfulness of complete skin clearance in psoriasis.

Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P.

J Am Acad Dermatol. 2016 Jul;75(1):77-82.e7. doi: 10.1016/j.jaad.2016.03.026. Epub 2016 May 17.

PMID:
27206759
18.

Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.

Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, Viswanathan HN, Gelfand JM.

J Am Acad Dermatol. 2016 Jun;74(6):1057-1065.e4. doi: 10.1016/j.jaad.2016.01.048. Epub 2016 Mar 4.

19.

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.

Mease PJ, Genovese MC, Mutebi A, Viswanathan HN, Chau D, Feng J, Erondu N, Nirula A.

J Rheumatol. 2016 Feb;43(2):343-9. doi: 10.3899/jrheum.150182. Epub 2016 Jan 15.

PMID:
26773108
20.

Psychometric Properties of the Asthma Symptom Diary (ASD), a Diary for Use in Clinical Trials of Persistent Asthma.

Globe G, Wiklund I, Lin J, Chen WH, Martin M, Mattera MS, von Maltzahn R, Feng JY, Chon Y, Viswanathan HN, Schatz M.

J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):60-6.e4. doi: 10.1016/j.jaip.2015.07.008. Epub 2015 Nov 6.

PMID:
26549745
21.

Where Does Water Go During Hydraulic Fracturing?

O'Malley D, Karra S, Currier RP, Makedonska N, Hyman JD, Viswanathan HS.

Ground Water. 2016 Jul;54(4):488-97. doi: 10.1111/gwat.12380. Epub 2015 Oct 15.

PMID:
26469857
22.

Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice.

Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, Yang W, Pinto L, Kircik L, Viswanathan HN.

J Dermatolog Treat. 2016;27(3):224-7. doi: 10.3109/09546634.2015.1093589. Epub 2015 Oct 7.

PMID:
26447179
23.

Geo-material microfluidics at reservoir conditions for subsurface energy resource applications.

Porter ML, Jiménez-Martínez J, Martinez R, McCulloch Q, Carey JW, Viswanathan HS.

Lab Chip. 2015 Oct 21;15(20):4044-53. doi: 10.1039/c5lc00704f. Epub 2015 Sep 2.

PMID:
26329326
24.

Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.

Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, Viswanathan HN, Doshi JA.

J Invest Dermatol. 2015 Dec;135(12):2955-2963. doi: 10.1038/jid.2015.296. Epub 2015 Jul 27.

25.

Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.

Wilson HD, Mutebi A, Revicki DA, Mease PJ, Genovese MC, Erondu N, Nirula A, Yuan FJ, Viswanathan HN.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1750-6. doi: 10.1002/acr.22653.

26.

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis.

Silverman SL, Wang A, Cheng L, Yang Y, Libanati C, Geller M, Grauer A, Nevitt M, Revicki D, Viswanathan HN.

Osteoporos Int. 2016 Jan;27(1):75-80. doi: 10.1007/s00198-015-3215-x. Epub 2015 Jul 15.

27.

Generalized lattice Boltzmann model for flow through tight porous media with Klinkenberg's effect.

Chen L, Fang W, Kang Q, De'Haven Hyman J, Viswanathan HS, Tao WQ.

Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Mar;91(3):033004. Epub 2015 Mar 3.

PMID:
25871199
28.

The experience of pain and redness in patients with moderate to severe plaque psoriasis.

Martin ML, Gordon K, Pinto L, Bushnell DM, Chau D, Viswanathan HN.

J Dermatolog Treat. 2015 Oct;26(5):401-5. doi: 10.3109/09546634.2014.996514. Epub 2015 Sep 4.

29.

Nanoscale simulation of shale transport properties using the lattice Boltzmann method: permeability and diffusivity.

Chen L, Zhang L, Kang Q, Viswanathan HS, Yao J, Tao W.

Sci Rep. 2015 Jan 28;5:8089. doi: 10.1038/srep08089.

30.

Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis.

Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, Klekotka P.

J Dermatolog Treat. 2015 Jun;26(3):235-9. doi: 10.3109/09546634.2014.943687. Epub 2014 Jul 31.

PMID:
25078334
31.

Probabilistic evaluation of shallow groundwater resources at a hypothetical carbon sequestration site.

Dai Z, Keating E, Bacon D, Viswanathan H, Stauffer P, Jordan A, Pawar R.

Sci Rep. 2014 Mar 7;4:4006. doi: 10.1038/srep04006.

32.

Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates.

Reynolds K, Viswanathan HN, Muntner P, Harrison TN, Cheetham TC, Hsu JW, Gold DT, Silverman S, Grauer A, Morisky DE, O'Malley CD.

Qual Life Res. 2014 Sep;23(7):2109-20. doi: 10.1007/s11136-014-0662-3. Epub 2014 Mar 7.

PMID:
24604077
33.

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.

Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG.

Br J Dermatol. 2014 Mar;170(3):705-15. doi: 10.1111/bjd.12636.

34.

Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory.

Bushnell DM, Martin ML, Scanlon M, Chen T, Chau D, Viswanathan HN.

Qual Life Res. 2014 Apr;23(3):897-906. doi: 10.1007/s11136-013-0527-1. Epub 2013 Sep 20.

PMID:
24052326
35.

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.

Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

PMID:
23868102
36.

Osteoporosis medication adherence: physician perceptions vs. patients' utilization.

Curtis JR, Cai Q, Wade SW, Stolshek BS, Adams JL, Balasubramanian A, Viswanathan HN, Kallich JD.

Bone. 2013 Jul;55(1):1-6. doi: 10.1016/j.bone.2013.03.003. Epub 2013 Mar 15.

37.

Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis.

Revicki DA, Jin Y, Wilson HD, Chau D, Viswanathan HN.

J Dermatolog Treat. 2014 Feb;25(1):8-14. doi: 10.3109/09546634.2013.769042. Epub 2013 Jun 11.

PMID:
23339373
38.

Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity.

Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, Gottlieb AB, Huang X, Globe D, Chau D, Viswanathan HN, Kricorian G.

J Dermatolog Treat. 2013 Aug;24(4):255-60. doi: 10.3109/09546634.2012.759639. Epub 2013 Jun 20.

PMID:
23249143
39.

Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.

Ward MA, Xu Y, Viswanathan HN, Stolshek BS, Clay B, Adams JL, Kallich JD, Fine S, Saag KG.

Osteoporos Int. 2013 Apr;24(4):1195-206. doi: 10.1007/s00198-012-2140-5. Epub 2012 Oct 26.

PMID:
23100119
40.

CO2/Brine transport into shallow aquifers along fault zones.

Keating EH, Newell DL, Viswanathan H, Carey JW, Zyvoloski G, Pawar R.

Environ Sci Technol. 2013 Jan 2;47(1):290-7. doi: 10.1021/es301495x. Epub 2012 Jul 30.

PMID:
22799449
41.

Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates.

Reynolds K, Viswanathan HN, O'Malley CD, Muntner P, Harrison TN, Cheetham TC, Hsu JW, Gold DT, Silverman S, Grauer A, Morisky DE.

Ann Pharmacother. 2012 May;46(5):659-70. doi: 10.1345/aph.1Q652. Epub 2012 Apr 17.

PMID:
22510666
42.

Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.

Viswanathan HN, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Wade SW.

Appl Health Econ Health Policy. 2012 May 1;10(3):163-73. doi: 10.2165/11598590-000000000-00000.

PMID:
22510025
43.

Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan.

Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN.

Bone. 2012 Apr;50(4):870-5. doi: 10.1016/j.bone.2011.12.021. Epub 2012 Jan 8.

PMID:
22245467
44.

The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy.

Kleinman L, Benjamin K, Viswanathan H, Mattera MS, Bosserman L, Blayney DW, Revicki DA.

Qual Life Res. 2012 Sep;21(7):1255-66. doi: 10.1007/s11136-011-0034-1. Epub 2011 Oct 11.

PMID:
21987032
45.

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.

Xu Y, Viswanathan HN, Ward MA, Clay B, Adams JL, Stolshek BS, Kallich JD, Fine S, Saag KG.

J Eval Clin Pract. 2013 Feb;19(1):50-9. doi: 10.1111/j.1365-2753.2011.01766.x. Epub 2011 Sep 13.

PMID:
21914091
46.

Greening coal: breakthroughs and challenges in carbon capture and storage.

Stauffer PH, Keating GN, Middleton RS, Viswanathan HS, Berchtold KA, Singh RP, Pawar RJ, Mancino A.

Environ Sci Technol. 2011 Oct 15;45(20):8597-604. doi: 10.1021/es200510f. Epub 2011 Sep 29.

PMID:
21905694
47.

Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.

Silverman S, Viswanathan HN, Yang YC, Wang A, Boonen S, Ragi-Eis S, Fardellone P, Gilchrist N, Lips P, Nevitt M, Palacios Gil-Antuñano S, Pavelka K, Revicki D, Simon J, Macarios D, Siris ES.

Osteoporos Int. 2012 Apr;23(4):1361-9. doi: 10.1007/s00198-011-1720-0. Epub 2011 Jul 19.

PMID:
21769664
48.

Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials.

Revicki DA, Stull D, Vernon M, Rader M, Tomita D, Viswanathan HN.

Qual Life Res. 2012 Mar;21(2):311-21. doi: 10.1007/s11136-011-9946-z. Epub 2011 Jun 5.

PMID:
21644007
49.

Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy.

Naeim A, Friedman L, Whitlock KB, Pasta DJ, Elkin EP, Lubeck DP, Viswanathan HN, Glaspy J.

J Oncol Pract. 2009 Sep;5(5):236-43. doi: 10.1200/JOP.091011.

50.

Mesoscale carbon sequestration site screening and CCS infrastructure analysis.

Keating GN, Middleton RS, Stauffer PH, Viswanathan HS, Letellier BC, Pasqualini D, Pawar RJ, Wolfsberg AV.

Environ Sci Technol. 2011 Jan 1;45(1):215-22. doi: 10.1021/es101470m. Epub 2010 Aug 10.

PMID:
20698546

Supplemental Content

Loading ...
Support Center